Aratana Therapeutics to Report Third Quarter Results

Conference Call and Webcast Scheduled for November 6, 2015 at 8:30 a.m. ET

KANSAS CITY, Kan., Oct. 29, 2015 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, will host a live conference call on Friday, November 6, 2015 at 8:30 a.m. ET to discuss financial results for the third quarter ending September 30, 2015. Interested participants and investors may access the conference call by dialing:
     1 (866) 364-3820 (U.S.)
     1 (855) 669-9657 (Canada)
     1 (412) 902-4210 (International)

Additionally, a live conference call from Aratana Therapeutics 2015 Investor Day will be held at the Grand Hyatt on Thursday, November 12, 2015 at 9 a.m. ET. The investor event will focus on the Company's R&D pipeline, commercialization of products and financial outlook. Interested parties are required to register to attend the event in person or may dial in using the conference line above.  

A replay of the third quarter results call will be available the same day of the event by approximately 11 a.m. ET and an audio webcast will be accessible for 90 days in the Aratana Investor Room. For a replay of the third quarter results call, use the below dial-in and conference ID 10075734:
     1 (877) 344-7529 (U.S.)
     1 (855) 669-9658 (Canada)
     1 (412) 317-0088 (International)

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The company's pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit

For investor inquires: 
Aratana Therapeutics, Inc.
Craig Tooman; (913) 353-1026

For media inquiries:
Tiberend Strategic Advisors, Inc.
Andrew Mielach; (212) 375-2694

SOURCE Aratana Therapeutics, Inc.

print email rss